Navigation Links
Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 7,906,489 which covers methods of Clostridium difficile infection (CDI) treatment with fidaxomicin.  The patent, which is eligible for listing in the U.S. Food and Drug Administration's Orange Book, also received a term adjustment of an additional 762 days for the USPTO's delay in the examination process which extends the patent term to March 2027.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"The issuance of this patent provides strong intellectual property protection for fidaxomicin, enhancing our drug candidate's present value," said Pedro Lichtinger, President and CEO of Optimer.  "Fidaxomicin is now protected by four issued patents and we are continuing our efforts to expand our patent portfolio for this important medical innovation."

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment CDI. In two Phase 3 trials, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  Most importantly, fidaxomicin reduced the risk of recurrence by 47% compared to vancomycin.  Optimer has filed marketing applications in the United States and the European Union for fidaxomicin for the treatment of CDI and for reducing the risk of recurrence when used for treatment of initial CDI.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fid
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... 1, 2015  Patients suffering from chronic plantar ... debilitating foot ailment, according to research presented at ... Annual Scientific Meeting . Researchers utilized ultrasound imaging ... remove diseased fasciitis tissue. Permanently removing damaged, pain-generating ... in its place, restoring normal function. ...
(Date:2/27/2015)... CHAPEL HILL, N.C. , Feb. 27, 2015 /PRNewswire/ ... evolved over the past decade but one thing hasn,t ... for MSLs to build relationships with Key Opinion Leaders. ... are recognized as the most valuable type of interaction, ... external limits on their KOL interactions. This is just ...
(Date:2/27/2015)... MARLTON, N.J. , Feb. 27, 2015  Acsis ... collaboration and serialization solutions, announced today that John ... as a Supply & Demand Chain Executive ... chain executives who are leading initiatives to help prepare ... challenges of today,s business climate. This year,s list of ...
Breaking Medicine Technology:Interventional radiology treatment relieves chronic plantar fasciitis 2Interventional radiology treatment relieves chronic plantar fasciitis 3Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
(Date:3/2/2015)... March 02, 2015 Secura Consultants ... relationship with First Protective Insurance Group of Birmingham, ... allow First Protective affiliated advisors to access the ... that Secura Consultants delivers. , Secura ... leader in the design and implementation of insured ...
(Date:3/1/2015)... Michigan (PRWEB) March 01, 2015 Women’s ... to treat Overactive Bladder (OAB) symptoms, such as a strong ... when another type of medication (anticholinergic) does not work well ... treatment option that takes another approach to targeting the source ... works on the nerves and bladder muscle, blocking the signals ...
(Date:3/1/2015)... IL (PRWEB) March 01, 2015 Ticket Down ... Dead in Chicago at Soldier Field. Deadheads have ... announced in January. , Grateful Dead was formed 50 years ... they were together as one until the untimely death of ... for combining different genres including blues, reggae, rock, bluegrass, folk, ...
(Date:3/1/2015)... California (PRWEB) March 01, 2015 Theme ... a new transition pack for Final Cut ... add accordion style transitions to any FCPX editors project.” ... given our users the tools needed to easily drag ... , The user gets many different controls over the ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 In ... Duncan Fletcher of Game Change Athlete ... Shannon Leinert about the benefits of athlete development and ... some of the unique challenges that athletes face and ... and future success. , Fletcher became involved in athlete ...
Breaking Medicine News(10 mins):Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) ... ruxolitinib can help people with the rare bone marrow disorder ... States under the brand name Jakafi, won,t cure myelofibrosis, it ... improve survival according to the studies. "This is ...
... Jenifer Goodwin HealthDay Reporter , WEDNESDAY, Feb. 29 ... much use in helping pregnant women quit smoking, a new ... Tobacco Control Studies at the University of Nottingham in England, ... weeks pregnant to one of two groups. Members of one ...
... not appear to be a factor in poor sleep, a new ... quality seems to improve over a lifetime, with the fewest complaints ... face of popular belief," said Michael Grandner, PhD, lead author of ... about sleep in older people men and women." The ...
... Orange, NJ -- Jordan Grafman, PhD, director of Traumatic Brain ... The 2nd Annual Traumatic Brain Injury Conference on March 6, ... long-term cognitive and social consequences of traumatic brain injury. A ... the influence of the location of brain injury and genetic ...
... HOUSTON - A drug that relieves the severe symptoms of ... survival of patients with the disease, according to a phase ... New England Journal of Medicine . "The Phase ... for many patients with myelofibrosis and now this phase III ...
... The Cognitive Neuroscience Society (CNS) invites members of the press ... in Chicago at the Palmer House Hotel. See the latest ... connections between sleep and memory, the neurological processes that govern ... in our lives. Highlights will include: , ...
Cached Medicine News:Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Nicotine Patches May Not Help During Pregnancy 2Health News:Nicotine Patches May Not Help During Pregnancy 3Health News:Study: Sleep gets better with age, not worse 2Health News:Kessler Foundation neuroscientist addresses 2nd Annual TBI Conference in Washington DC 2Health News:Drug improves survival and quality of life for people with myelofibrosis 2Health News:Drug improves survival and quality of life for people with myelofibrosis 3
... The Modular Shoulder System* ... surgeons with a comprehensive range ... of individual patient needs. With ... Smith + Nephew offers a ...
... The Bio-Modular, for ... shoulder replacement. Modularity in ... range of sizing and ... with one of the ...
... The Bigliani/Flatow shoulder allows for the ... cases of shoulder replacement surgery. Backed ... and decades of experience, the Bigliani/Flatow ... the natural shoulder's mobility, balance, and ...
Comprehensive, unified system for total or hemi shoulder arthroplasty....
Medicine Products: